New Zealand’s regulatory authority Medsafe on Thursday granted provisional approval of the AstraZeneca Covid-19 vaccine for people aged 18 and above.
New Zealand secured 7.6 million doses of the AstraZeneca vaccine, sufficient for 3.8 million people, by means of an advance buy settlement with the corporate final 12 months, Acting Minister for Covid-19 Response Ayesha Verrall mentioned in an announcement.
“The AstraZeneca vaccine is one in every of 4 buy agreements we’ve with pharmaceutical firms for Covid-19 vaccines. We took a portfolio method to handle the danger that some vaccines won’t full trials or be permitted for use in New Zealand,” Xinhua information company quoted Verrall as saying.
“We are in a lucky place to now have three vaccines obtain provisional approval. Cabinet is but to contemplate whether or not to make use of the AstraZeneca Covid-19 vaccine in New Zealand,” she mentioned.
However, this is a crucial step in the direction of enabling the donation of AstraZeneca from New Zealand to Pacific international locations, the place we’ve made commitments, Verrall mentioned.
The AstraZeneca vaccine requires two doses and is saved at regular fridge temperatures (2 to eight levels Celsius).
The first supply might be as early as late August, and officers are working intently with AstraZeneca to verify supply schedules.
The immunisation plan in New Zealand stays centered on rolling out the Pfizer vaccine. The workforce is ramping up in step with elevated deliveries, Verrall mentioned.
“We are on monitor to supply two doses of the Pfizer vaccines to everybody in New Zealand who needs to have one, by the tip of this 12 months. No one will miss out,” she added.
Latest World News